American Century Companies’s PTC Therapeutics PTCT Stock Holding History

American Century Companies’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.9M	Buy	500,995 +495,992	+9,914%	+$35.8M	0.02%	954
2026 Q1	$341K	Buy	5,003 +414	+9%	+$29.3K	﹤0.01%	2612
2025 Q4	$349K	Sell	4,589 -13,568	-75%	-$986K	﹤0.01%	2603
2025 Q3	$1.11M	Sell	18,157 -25,687	-59%	-$1.34M	﹤0.01%	2267
2025 Q2	$2.14M	Sell	43,844 -12,409	-22%	-$589K	﹤0.01%	2005
2025 Q1	$2.87M	Sell	56,253 -3,897	-6%	-$194K	﹤0.01%	1847
2024 Q4	$2.72M	Buy	60,150 +24,090	+67%	+$1.03M	﹤0.01%	1865
2024 Q3	$1.34M	Sell	36,060 -1,334	-4%	-$44.7K	﹤0.01%	2132
2024 Q2	$1.14M	Buy	37,394 +19,475	+109%	+$631K	﹤0.01%	2128
2024 Q1	$521K	Sell	17,919 -7,789	-30%	-$218K	﹤0.01%	2436
2023 Q4	$709K	Buy	25,708 +2,058	+9%	+$47.1K	﹤0.01%	2217
2023 Q3	$530K	Buy	23,650 +1,459	+7%	+$54.3K	﹤0.01%	2244
2023 Q2	$903K	Buy	22,191 +13,609	+159%	+$666K	﹤0.01%	1988
2023 Q1	$416K	Buy	8,582 +545	+7%	+$24.9K	﹤0.01%	2192
2022 Q4	$307K	Sell	8,037 -8,407	-51%	-$349K	﹤0.01%	2208
2022 Q3	$825K	Buy	16,444 +6,274	+62%	+$307K	﹤0.01%	1767
2022 Q2	$407K	Sell	10,170 -3,000	-23%	-$105K	﹤0.01%	1983
2022 Q1	$492K	Hold	13,170	–	–	﹤0.01%	1973
2021 Q4	$525K	Hold	13,170	–	–	﹤0.01%	1909
2021 Q3	$490K	Buy	+13,170	New	+$541K	﹤0.01%	1886
2021 Q1	–	Sell	-10,079	Closed	-$615K	–	2243
2020 Q4	$615K	Sell	10,079 -3,010	-23%	-$177K	﹤0.01%	1471
2020 Q3	$612K	Sell	13,089 -200,952	-94%	-$9.89M	﹤0.01%	1266
2020 Q2	$10.9M	Buy	214,041 +16,993	+9%	+$835K	0.01%	657
2020 Q1	$8.79M	Buy	197,048 +10,673	+6%	+$537K	0.01%	626
2019 Q4	$8.95M	Buy	186,375 +76,061	+69%	+$3.23M	0.01%	710
2019 Q3	$3.73M	Buy	110,314 +6,574	+6%	+$286K	﹤0.01%	863
2019 Q2	$4.67M	Buy	+103,740	New	+$4.1M	﹤0.01%	851
2018 Q4	–	Sell	-69,384	Closed	-$3.26M	–	1323
2018 Q3	$3.26M	Sell	69,384 -22,658	-25%	-$938K	﹤0.01%	939
2018 Q2	$3.1M	Hold	92,042	–	–	﹤0.01%	939
2018 Q1	$2.49M	Sell	92,042 -99,399	-52%	-$2.52M	﹤0.01%	965
2017 Q4	$3.19M	Sell	191,441 -5,281	-3%	-$89.4K	﹤0.01%	923
2017 Q3	$3.94M	Buy	+196,722	New	+$3.85M	﹤0.01%	913
2016 Q1	–	Sell	-23,651	Closed	-$766K	–	1364
2015 Q4	$766K	Sell	23,651 -11,377	-32%	-$335K	﹤0.01%	1145
2015 Q3	$935K	Buy	35,028 +10,957	+46%	+$469K	﹤0.01%	1130
2015 Q2	$1.16M	Buy	24,071 +13,430	+126%	+$784K	﹤0.01%	1125
2015 Q1	$648K	Sell	10,641 -21	-0.2%	-$1.28K	﹤0.01%	1208
2014 Q4	$552K	Buy	+10,662	New	+$469K	﹤0.01%	1272

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

American Century Companies's PTCT Position: Q2 2026 in Review

American Century Companies increased its PTC Therapeutics (PTCT) stake by 9,914% in Q2 2026, buying an estimated $35.8M and bringing the position to 500,995 shares worth $40.9M. The position accounts for 0.02% of the portfolio, ranked #954.

American Century Companies first reported a position in PTCT in Q4 2014 and has held it in 37 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

American Century Companies held 500,995 shares of PTC Therapeutics worth $40.9M as of Q2 2026.
American Century Companies bought 495,992 PTC Therapeutics shares in Q2 2026, an estimated $35.8M.
PTC Therapeutics made up 0.02% of American Century Companies's portfolio in Q2 2026, its #954 holding.
American Century Companies first reported a position in PTC Therapeutics in Q4 2014 and has held it in 37 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.